Loading...
Publication: Management of drug-resistant tuberculosis
Lange, C Dheda, K Chesov, D Mandalakas, A.M Udwadia, Z Horsburgh, C.R
Lange, C
Dheda, K
Chesov, D
Mandalakas, A.M
Udwadia, Z
Horsburgh, C.R
Citations
Altmetric:
Abstract
Drug-resistant tuberculosis is a major public health concern in many countries. Over the past decade, the number of patients infected with Mycobacterium tuberculosis resistant to the most effective drugs against tuberculosis (ie, rifampicin and isoniazid), which is called multidrug-resistant tuberculosis, has continued to increase. Globally, 4·6% of patients with tuberculosis have multidrug-resistant tuberculosis, but in some areas, like Kazakhstan, Kyrgyzstan, Moldova, and Ukraine, this proportion exceeds 25%. Treatment for patients with multidrug-resistant tuberculosis is prolonged (ie, 9–24 months) and patients with multidrug-resistant tuberculosis have less favourable outcomes than those treated for drug-susceptible tuberculosis. Individualised multidrug-resistant tuberculosis treatment with novel (eg, bedaquiline) and repurposed (eg, linezolid, clofazimine, or meropenem) drugs and guided by genotypic and phenotypic drug susceptibility testing can improve treatment outcomes. Some clinical trials are evaluating 6-month regimens to simplify management and improve outcomes of patients with multidrug-resistant tuberculosis. Here we review optimal diagnostic and treatment strategies for patients with drug-resistant tuberculosis and their contacts.
Description
Date
2019-09-14
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier Ltd
Collections
Research Projects
Organizational Units
Journal Issue
Keywords
Drug-resistant tuberculosis,Mycobacterium tuberculosis,Drugs
Citation
Lange C, Dheda K, Chesov D, Mandalakas AM, Udwadia Z, Horsburgh CR. Management of drug-resistant tuberculosis. The Lancet. 2019;394(10202):953-66. DOI: https://doi.org/10.1016/S0140-6736(19)31882-3.